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I. Introduction: Myeloid-derived suppressor cells (MDSCs) comprise immature myeloid populations produced in a wide range of human cancers, including ovarian carcinoma, and play significant tumor-promoting roles by suppressing adaptive immunity and by providing a rich source of angiogenic factors 1 . MDSCs are composed of two major subsets, monocytic and granulocytic, the proportion of each is influenced by the types of tumor-derived factors (TDFs) secreted in vivo 1, 2 . Although much attention has focused on understanding how MDSCs function, a larger gap has remained in our understanding of mechanisms that govern their development. To that end, our original proposal addressed the novel concept that the overproduction of granulocyte-colony stimulating factor (G-CSF) in ovarian carcinoma facilitates MDSC accumulation. This notion was originally born from studies in our laboratory, which revealed a prominent role of G-CSF in the generation of MDSCs in mouse models of mammary carcinoma 3, 4 While we believe the rationale for this hypothesis remained sound, we serendipitously discovered that the levels of IL-8 (CXCL8) and IL-6 overshadowed all other cytokines/chemokines tested, including G-CSF. Thus, in contrast to mammary tumor models, we identified a different set of pro-inflammatory cytokines potentially linked to MDSC accumulation in ovarian cancer. Given these striking new findings, we refined our original hypothesis to reflect tumor-derived 
(year 1) or IL-6 (year 2), in lieu of G-CSF as major elements of MDSC-mediated ovarian tumor progression.
The following is a detailed account of our progress made for each aim and task with respect to the original SOW.
II. Body (from Original SOW):

Specific Aim 1: To quantify G-CSF levels in human ovarian cancer cell lines, and then evaluate the ability of selected G-CSF-producing cell lines to generate MDSC using human-mouse xenograft models
Task 1a, 1b and 2a, completed in year-1; Tasks 2b -2d, completed in year-2, and are summarized below.
Task 1a:
Cell-free supernatants of human ovarian cancer cell lines will be quantified for G-CSF levels. Both metastatic SKOV-3 and NIH:OVCAR-3 cell lines (from ATCC) will be analyzed, since both have been shown to express G-CSF.
Progress:
We determined that both cell lines produced G-CSF as expected. However, the concentrations were also lower than expected. Therefore, before pursuing subsequent studies, we embarked on a more comprehensive analysis of tumor-derived cytokines and chemokines, focusing on two key characteristics: association with MDSC biology and cross-reaction in human-mouse xenograft models. In so doing, we compiled a list of 12 cytokines and chemokines, including G-CSF and analyzed them by Luminex multiplex technology ( Fig. 1A and 1B). While our findings confirmed G-CSF production by ELISA (< 100 pg/ml), we identified an additional five factors that were highly produced, most notably IL-8 which was common to both cell lines. IL-8 levels exceeded 2 ng/ml/10 6 cells/24 hr.
A. B.
Figure 1. Cytokine production by ovarian carcinoma cell line models. Cell-free culture supernatants were analyzed by Luminex technology for the indicated TDFs. Data reported as pg/ml/10 6 cells/24 hr.
Task 1b: RNA will be collected from the cells to verify G-CSF message levels by RT-PCR or real-time PCR.
Progress: Since our protein data was most revealing, we did not pursue molecular analysis of G-CSF in our cell line model, but confirmed IL-8 message.
Task 2a: Evaluate the ability of ovarian tumor cell lines to produce G-CSF and generate granulocytic MDSC in vivo.
Progress:
We proceeded with orthotropic implantation of each cell line. Both cell lines were tumorigenic in vivo; however, SKOV3 seemed to be more tumorigenic than NIH:OVCAR-3, based on time to morbidity (Fig. 2) . Therefore, since SKOV3 was more aggressive, we opted to pursue this cell line first in subsequent experiments.
Task 2b: Sera G-CSF and MDSC levels will be determined and tracked biweekly during the course of tumor growth. Age/gender-matched non-tumor-bearing mice will serve as controls for G-CSF and MDSC values at all measurable time-points.
Based on results in Task 1, we analyzed sera for IL-8 levels. However, in regard to MDSC quantification, we focused on the spleen as a systemic reservoir for the accumulation of MDSCs during tumor-bearing conditions. Data are further discussed below.
Task 2c: When mice appear moribund (as evidence of advanced disease), mice will be euthanized and spleens and ascites (tumor site) collected. Blood will also be collected as part of a terminal bleed. Single cell suspensions will be made from splenic and tumor sites, and cryopreserved for subsequent studies.
Completed; all cells and tissues collected as proposed.
Tasks 2d:
Murine granulocytic MDSCs will be defined by their CD11b + Ly6C lo Ly6G + phenotype by flow cytometry, granulocytic morphology by Wright-Giemsa staining and ability to inhibit T cell proliferation.
Progress: Analysis of MDSC frequencies in the spleen revealed significant levels of MDSCs, particularly of granulocytic phenotype, relative to the non-tumor-bearing control mice (Fig. 3) . This was observed in both tumor cell line models, indicating that ovarian carcinoma can generate MDSCs in vivo. Morphologic studies in an independent model of mammary carcinoma confirmed that the MDSCs expressing this phenotype were granulocytic. T cell proliferation studies were suspended due to exhausted funds. 
A. B.
Moreover, in the section on 'Potential Problems & Alternative Strategies' in Aim 1 of the project narrative, we pointed out that in addition to or in lieu of the human-mouse xenograft model, we would consider testing our hypothesis in a fully syngeneic immune competent mouse model of metastatic ovarian cancer. To that end, we extended our analysis to an implantable mouse model of ovarian cancer, termed ID8 (Fig. 4) . Unfortunately, in contrast to the human cell lines, ID8 did not produce significant levels of IL-8 (known as KC in mice), as measured in the ascites of the peritoneal cavity (Fig. 4A ). Instead, we observed significant levels of IL-6 in the metastatic tumor-bearing (TB) microenvironment relative to peritoneal fluid collected from nontumor-bearing (NTB) control mice (Fig. 4B ). Moreover, we observed significant increases in the frequency and absolute numbers of F4/80 + monocytes/macrophages in tumor-bearing hosts compared to those from the NTB controls ( Fig. 4C and 4D ). These differences were observed both in the periphery (i.e., spleen) and tumor microenvironment (i.e., ascites). Importantly, these observations recapitulated key findings made with patient samples (see Aim 3).
A.
B. We then reasoned that if IL-6 played an important role in myeloid-mediated mechanisms of tumor progression, then neutralizing IL-6 in vivo using neutralizing anti-IL-6 antibody should improve overall survival. However, efforts to inhibit tumor progression via IL-6 blockade during the no cost extension period were unsuccessful.
C. D.
Milestones for Aim 1:
We completed major elements of this aim, although with mixed results. First, we identified ovarian tumor cell line models that are tumorigenic in vivo. Secondly, tumor growth was accompanied by a significant MDSC response, largely due to the accumulation of the granulocytic subset. And thirdly, while we did confirm the production of G-CSF, the levels of G-CSF response dwarfed in comparison to IL-8 production in both human cell line models tested. Unfortunately, using a relevant syngeneic mouse model of ovarian cancer (ID8), we identified IL-6 instead of IL-8 as 'cytokine/myeloid cell signature' associated with tumor progression. Undoubtedly, our inability to corroborate G-CSF, IL-8 and/or IL-6 production in the all tumor models tested compromised the extent of overall positive progress. Nonetheless, we continued to move forward in Aims 2 and Aim 3 as follows.
Specific Aim 2: To examine the causal link between tumor-derived G-CSF production and granulocytic MDSC development using loss-of-function approaches
Task 1a: To generate ovarian tumor cell lines in Aim 1 deficient in G-CSF production by shRNAbased methodologies via our shRNA core facility.
Progress: Based on our human data in Aim 1, we replaced G-CSF with IL-8. At that time, we decided to focus on one cell line, SKOV3, due to its ability to grow more reliably and aggressively than NIH:OVCAR-3 (Fig. 6 ). The various sublines were successfully generated.
Task 1b:
Analyze and verify the efficiency of gene knockdown in the different populations via real-time PCR analysis and ELISA.
Progress: Completed; characterization of the different sublines revealed varying degrees of IL-8 knockdown relative to the control (Fig. 6A ). The magnitude of knockdown was confirmed by ELISA (Fig. 6B ). Based on these criteria, we selected construct 1 for subsequent studies.
A. P < 0.003 B. P < 0.03 Figure 6 . Progress: IL-8 knockdown did not alter in vitro proliferation (Fig. 7A) .
A. B.
Milestones for Task 1: Development and characterization of human ovarian tumor cell lines that are stably silenced for G-CSF production. For each tumor cell line, two populations will be generated, one deficient in G-CSF and the other serving as the vector control.
Progress:
We achieved major elements of this aim and had produced both control and IL-8-deficient sublines (see Figs. 6 and 7).
Task 2a:
To evaluate the effect of G-CSF-deficiency on tumor growth; collection of serum, lymphoid and tumor tissues from mice for subsequent phenotypic and functional analyses.
Progress:
Completed for the SKOV3 model.
Task 2b:
For proof-of-concept, emphasis will be on the endpoint analysis. When mice appear moribund as evidence of advanced disease, mice will be euthanized and splenocytes, ascites and serum collected and stored as in Aim 1/Task 2.
Progress:
Completed for the SKOV3 model. Interestingly, we observed a significant increase in overall survival in mice bearing the IL-8-deficient subline compared to the control (Fig. 7B ).
Milestones for Task 2:
Determination of the impact of G-CSF-deficiency on orthotopic tumor growth using two different ovarian tumor models.
Progress:
Completed for the SKOV3 model. Altogether, these data were promising and suggest an important role of tumor-derived IL-8 production in ovarian cancer progression.
Task 3a:
To analyze serum G-CSF levels and MDSC accumulation in both lymphoid and tumor tissues (Experiments will be staggered so the different tumor models will be analyzed at different times).
Progress:
Completed for the SKOV3 model. First, we observed a significant difference in IL-8 levels, pre-vs. post-tumor challenge in mice bearing either the vector control or IL-8-deficient subline. Whereas, pre-bleeds showed no detectable IL-8, post-bleeds revealed significant amounts of circulating IL-8 ( Fig. 8A and 8B) . Importantly, the level of IL-8 in sera of mice bearing the IL-8-deficient subline was significantly lower compared to the scramble control (Fig.  8C ). The post-bleeds were taken at endpoint when all mice appeared moribund. These data not only validate the IL-8 phenotype in vivo, but also demonstrated a correlation with survival.
A. B. C.
Task 3b:
Thaw splenocytes, and analyze for granulocytic MDSC levels (percentages/absolute numbers) based on CD11b + Ly6C lo Ly6G + phenotype by flow cytometry.
Task 3c: Purify splenic granulocytic MDSCs using magnetic bead cell separation kits and identify/verify cellular morphology based on Wright-Giemsa staining.
Task 3d: Assess purified myeloid cells for their ability to activate/inhibit T cell activity in vitro (via 3 H-thymidine assays).
Task 3e: Analyze single cell suspensions from ascites for MDSC characteristics, as in Aim 3/Tasks 3b -3d.
Progress: Experiments in Tasks 3b -3e were suspended due to exhausted funds.
Task 4a:
To analyze the effect of G-CSF blockade on MDSC accumulation using a neutralizing anti-G-CSF monoclonal antibody.
Task 4b: Spleens and tumor tissues will be collected 24 -48 hr after the final mAb injection. MDSC levels/function will then be assessed as in Aim 2/Task 3.
Progress:
Experiments in Tasks 4a -4b were suspended due to exhausted funds.
Overall Milestones for Aim 2:
Thus far, our human data supported the hypothesis that tumorderived IL-8 played an important role in tumor progression. However, our mouse ID8 studies suggested that IL-6 did so (Aim 1). Given the complexity or in consistency of these findings, we conducted parallel studies in patient samples, which are detailed below in Aim 3. 
Specific Aim 3: To measure circulating G-CSF and MDSC levels in ovarian carcinoma patients and then correlate potential changes in both parameters with clinical outcome measurements.
Tasks 1 and 2:
Comprehensive cytokine/chemokine analysis completed for cancer patients (n=21) and matched controls (n=5). As we reported in year-1, we identified six cytokines and chemokines associated with aberrant myelopoiesis in ovarian cancer (Fig. 9 ). In year-2, we investigated the potential clinical merit of these six myelopoietic factors based on newly acquired de-identified patient data, and found significant inverse relationships between IL-6 with patient outcome. Specifically, our data indicated that rising IL-6 levels portended worse overall survival (hazard ratio = 1.525, P = 0.02).
Figure 9 Figure 10
Since we originally hypothesized that ovarian cancer disables antitumor immunity through disruption of normal myeloid cell differentiation, we next examined patient blood for evidence of expanded myeloid populations relative to matched donors. Using multi-parameter flow cytometry, we compared 21 ovarian cancer patients reflecting stages II -IV to 22 gender-raceand age-matched controls. All patient peripheral blood samples were obtained at diagnosis through the Data Bank and Biorepository (DBBR) at Roswell Park, and the mononuclear fraction was cryopreserved. We reasoned that patients with advance disease, such as stages II -IV, would best illustrate the relationship between MDSC frequencies in health vs. disease.
Our data demonstrated a significant increase in 2 of the 3 myeloid populations tested, both sharing a myelo-monocytic phenotype (i.e., CD33 + CD15 -HLA-DR -myeloid-derived suppressor cell/MDSCs or CD33 + CD15 -HLA-DR + monocytes) compared to the matched donors (Fig. 10) . Thus, we identified a potential 'cytokine/myeloid cell type' profile portending a poorer prognosis. To explore this idea in more detail, we plotted the relationship between IL-6 levels and myeloid cell type (using data from Figs. 9 and 10). As a result, we identified a highly significant positive correlation between IL-6 levels and monocyte frequency (Fig. 11) . No other significant association was observed, strengthening the potential relevance of the IL-6/myelo-monocytic profile in ovarian cancer patient assessment.
To further validate the potential relevance of IL-6 in vivo, we examined IL-6 levels by ELISA in the metastatic tumor microenvironment (i.e., ascites) in a total of 80 ovarian cancer patients (Fig. 12, left column) . Our data showed that the majority of patients tested produced robust levels of IL-6. Similar results were seen in an 11-patient subgroup in which matched sera were also tested (Fig. 12, right column) . Progress: Studies were suspended due to insufficient funds.
Milestones/Overall Progress for Aim 3:
Of the six cytokines identified, only IL-6 fulfilled three important clinical criteria. Altogether, we found that the levels of IL-6: 1) were significantly higher in patients than matched healthy donors; 2) strongly correlated with the accumulation of myeloid populations commonly observed in patients with ovarian cancer; and 3) were inversely associated with patient outcome; that is, rising IL-6 levels portended worse overall survival (hazard ratio = 1.525, P = 0.02).
Key Research Accomplishments (collectively from all 3 Aims):
Altogether, we identified:
• A significant accumulation of two distinct myelo-monocytic subsets in the peripheral blood of ovarian cancer patients reflecting stages II -IV (all relative to healthy donors).
• Six pro-inflammatory cytokines in matched patient sera, including IL-8, G-CSF, M-CSF, IL-6, TNF- and VEGF-A (all relative to healthy donors). However, only IL-6 levels were significantly and positively associated with poorer clinical outcome, as determined by hazard ratio assessment.
• A significant and positive relationship between IL-8 levels and MDSC accumulation in a human-mouse xenograft model (SKOV3). IL-8 knockdown in SKOV3 cells significantly improved overall survival.
• A significant and positive relationship between IL-6 levels and myelo-monocytic frequencies in an immune competent mouse model of ovarian carcinoma (ID8).
Data in Figures 2 and 3 were re-plotted to determine potential correlations between the indicated parameters.
IL-6 levels in patient ascites were quantified by ELISA from the indicated number of patients with advanced disease. Right column refers to 11 of the 80 patients in which matched sera were also tested (see Figure 2) . Horizontal line in graph refers to mean.
Reportable Outcomes:
Not applicable during this total award period.
Conclusions:
During this funding period, we have been testing the underlying hypothesis that tumor-derived signals (i.e., cytokines) perturb normal myelopoiesis resulting in the expansion of myeloid populations that paradoxically harbor tumor-promoting rather than tumorsuppressing activities. In year-2, we focused on the potential clinical merit of the six myelopoietic factors previously identified in year-1. Interestingly, of the six cytokines identified IL-6 but not G-CSF, IL-8, M-CSF, TNF- or VEGF, fulfilled three important clinical criteria and were recapitulated in a syngeneic mouse model of ovarian cancer (ID8). Surprisingly, IL-6 blockade failed to extend survival in the ID8 model; albeit, the reasons for this remain unclear and require further study. Nonetheless, based on the patient data, we found that the levels of IL-6: 1) were significantly higher in patients than matched healthy donors; 2) strongly correlated with the accumulation of myeloid populations commonly observed in patients with ovarian cancer; and 3) were inversely associated with patient outcome; that is, rising IL-6 levels portended worse overall survival (hazard ratio = 1.525, P = 0.02). The discovery of this new axis in myeloid-ovarian cancer biology has important implications for IL-6-based clinical interventions. Tracking changes in IL-6 levels, systemically or within the tumor microenvironment, along with other clinical parameters, may serve as a novel 'biomarker' signature for disease status or response to therapy. Moreover, these studies provide the rationale to target IL-6 for therapeutic purposes in at least subsets of ovarian cancer patients. The proposed research will study the association between MDSCs and ovarian cancer prognosis. Such data will be used in designing/identifying promising novel immunotherapeutic approaches. Overlap: None C028252 (Repasky, PI; Abrams, Co-I) 9/1/13 -8/31/15 NYS Dept. of Health Peter T. Rowley Breast Cancer Scientific Research Projects "Is the immune response against breast cancer inhibited by lack of available metabolic energy?" The overall goal is to explore the mechanisms by which energy allocation, modulated by ambient temperature and dietary fat, impacts the antitumor immune response and implement these findings to improve the outcome of breast cancer therapy. 
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